Markets open

AbbVie Inc.

ABBV · NYSE

Sep 2026upcoming

Next quarter

Consensus is $3.87 EPS for Sep 2026 across 5 estimates, ranging $3.84 to $3.95.

ABBV Jun 2026

Reported Jul 31, 2026

Beat 0.27%

EPS estimate: $3.64
EPS actual: $3.65
Revenue estimate: —
Revenue actual: —
1-day move: -2.33%

Call highlights have not been generated for this quarter.

Symbol: ABBV
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: NYSE

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology - and products and services in our Allergan Aesthetics portfolio.

Key Issues

Bullish view

AbbVie has diversified beyond Humira, with Skyrizi, Rinvoq and neuroscience businesses delivering strong growth and supporting a $300 million increase in 2026 revenue guidance.

Bearish view

The Apogee acquisition is already reducing 2026 EPS guidance and increasing research spending, showing that replacing lost legacy economics may carry meaningful near-term costs.